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Abstract
The causes of most neurodegenerative diseases, including sporadic Alzheimer’s disease (AD), remain enigmatic. There is,
however, increasing evidence implicating mitochondrial dysfunction resulting from deafferentiation of disconnected neural
circuits in the pathogenesis of energy deficit in AD. The patterns of reduced expression of both mitochondrial DNA
(mtDNA) and nuclear DNA (nDNA) encoded genes is consistent with a physiological down-regulation of the mitochondrial
respiratory chain in response to reduced neuronal activity. On the other hand, the role(s) of somatic cell or maternally
inherited mtDNA mutations in the pathogenesis of mitochondrial dysfunction in AD are still controversial. ß 1999
Elsevier Science B.V. All rights reserved.
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1. Introduction
Mitochondria are the main sources of energy in
the cell. They contain their own DNA (mtDNA),
which encodes 13 components of the respiratory
chain [1]. Mitochondria are maternally inherited,
and are critical for the normal functioning of tissues
that are highly dependent on aerobic metabolism,
such as brain and muscle.
Alzheimer’s disease (AD) is a major form of de-
mentia, a¡ecting 5^15% of the population over the
age of 65 years [2]. Clinically, the disease is mani-
fested by memory loss and unremitting mental dete-
rioration. While many patients with autosomal dom-
inant familial AD have mutations in the amyloid
precursor protein (APP) or presenilin genes [3^5],
most patients with AD are sporadic cases, in whom
no such mutations have been identi¢ed, and etiology
and pathogenic mechanisms of neuronal dysfunction
remain unknown.
Recently, attention has been directed to the possi-
ble contribution of mitochondrial dysfunction and
oxidative damage in late-onset neurodegenerative
disorders, including the familial and sporadic forms
of AD [6^8]. This review focuses on the role of mi-
tochondria in AD, and summarizes some of the rel-
evant neuropathological, biochemical, and molecular
genetic data.
2. Neuropathology
The histopathology of the AD brain shows loss of
neurons and two hallmark lesions: neuro¢brillary
tangles (NFT) and neuritic plaques (NP) [9]. The
tangles are composed primarily of abnormally phos-
phorylated tau microtubule-associated protein;
plaques consist mainly of aggregates of a 40^42 ami-
no acid polypeptide derived from the proteolytic
processing of APP.
The neocortex and hippocampus are both severely
a¡ected in AD, but the pathology does not a¡ect all
cell types. The pyramidal neurons in the entorhinal
cortex and the CA1 and subiculum regions of the
hippocampus are vulnerable to NFT formation, but
the CA3 region and the granule cells in the dentate
gyrus are resistant to degeneration [10]. In the neo-
cortex, subsets of pyramidal neurons are susceptible
to NFT formation and degeneration, and inhibitory
interneurons do not show NFT and are resistant to
degeneration [11,12]. The pyramidal neurons that
form the long cortico-cortical projections are also
a¡ected in AD, but primary sensory and motor areas
show only minor neuronal loss [13,14].
The most profoundly a¡ected circuit in the cere-
bral cortex is the perforant pathway, which origi-
nates in layer II of the entorhinal cortex and termi-
nates in the outer molecular layer of the dentate
gyrus, thus providing the key connection between
the neocortex and the hippocampus [15]. The ento-
rhinal cortex is an area of extensive convergence of
inputs from association areas of the neocortex which,
in turn, transmits processed information to the den-
tate gyrus of the hippocampus and thereby plays a
critical role in memory [16]. The perforant pathway
is invariably damaged by extensive NFT formation
in AD, even at early stages of the disease [17]. In
addition, there is signi¢cant loss of synapses in asso-
ciation areas, indicating structural damage to neural
circuits [13,14]. Regarding subcortical projections,
the thalamic projections are spared, but the choliner-
gic projection from the nucleus basalis of Meynert is
a¡ected early in the course of the disease [18].
It is now well documented that neuronal degener-
ation in AD is extensive, but selective. Given the
circuits that degenerate, it is not surprising that sev-
eral spheres of higher mental functions are a¡ected,
including learning, behavior, and memory.
3. The mitochondrion and mtDNA mutations
The mitochondrial respiratory chain comprises ¢ve
multisubunit proteins (Complexes I^V) located on
the inner membrane, and is the most important
source of superoxide radicals in aerobic cells.
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All 13 proteins encoded by mtDNA are part of the
respiratory chain/oxidative phosphorylation system
[1].
Mutations of mitochondrial DNA, including ma-
ternally inherited point mutations and large-scale
sporadic mtDNA rearrangements have been associ-
ated with a wide spectrum of human diseases [19,20].
The main disorder associated with sporadic rear-
rangements of mtDNA is Kearns-Sayre syndrome
(KSS), a multisystemic syndrome characterized by
paralysis of the extraocular muscles, pigmentary ret-
inopathy, heart block, cerebellar ataxia, and elevated
CSF protein. The mtDNA rearrangements, which
are predominantly deletions (v-mtDNAs) are large
(up to 9 kb in size) and are present at levels of up
to 80% of total mtDNA (i.e. patients are heteroplas-
mic, with a mixture of normal and deleted mtDNAs).
The size and location of the deletion, and the pro-
portion of v-mtDNA, varies among patients, but one
particular v-mtDNA, in which 4977 bp have been
deleted, has been found in about 1/3 of all patients:
this 5-kb deletion has therefore been called the ‘com-
mon deletion’ [21,22]. Deleted mtDNAs are tran-
scribed into RNA, but are not translated, because
the deletions remove essential tRNAs that are re-
quired for protein synthesis [23]. Therefore, even
genes outside the deletion are not translated.
Tissues from normal aged individuals, and espe-
cially long-lived postmitotic tissues with high oxida-
tive requirements, such as muscle and brain, contain
low amounts (detectable only by the polymerase
chain reaction, or PCR) of the same v-mtDNAs
found in much greater abundance in patients with
sporadic KSS [24,25]. These v-mtDNAs accumulate
during aging. It has been shown that the ‘common
deletion’ accumulates in muscle by a factor of 10 000
over the course of the normal human lifespan, reach-
ing a level of approximately 0.1% of total muscle
mtDNA by age 84 years [26]. Numerous other de-
leted species are also present in aging human muscle
[27^29]. In addition, there is focal accumulation of
the ‘common deletion’ (used as a surrogate marker to
represent all possible mtDNA deletions) in regions of
aging human brains [30,31]. The regions with the
highest levels are the striatum (caudate and puta-
men), the cerebral cortex, and the substantia nigra
in the midbrain; in contrast, cerebellum contains rel-
atively low levels of deletions.
4. Oxidative stress and damage in AD
Although numerous hypotheses have been pro-
posed for the pathogenesis of sporadic AD, the exact
mechanism remains poorly understood. One hypoth-
esis that has received considerable attention postu-
lates the possible involvement of oxygen free radicals
and hydrogen peroxide [32^35]. The oxidative stress
hypothesis proposes that some as yet unknown fac-
tors cause an imbalance that favours the generation
of reactive oxygen species (ROS) over antioxidant
defenses, leading to oxidative damage of neuronal
lipids, proteins, and DNA. Important factors that
may favor oxidative stress in the brain in AD include
the brain’s high oxygen consumption rate, the abun-
dant polyunsaturated fatty acid content, the short
half-life of mtDNA (V30 days in rat [6]), and a
relative lack of antioxidant defenses compared to
other tissues [36].
During the past 5 years, there has been increasing
interest in the role of free radicals in neurodegener-
ative diseases [7,8,36]. However, there is little direct
information about ROS in the brain in AD. Smith et
al. [37] and Hensley et al. [38] have suggested that
increased oxidative stress in the brain in aging and in
AD is re£ected by increased protein oxidation.
Others have shown signi¢cantly increased levels of
lipid peroxidation in AD brains, indicated by eleva-
tions of thiobarbituric acid-reactive compounds in
the hippocampus, pyriform cortex, and amygdala
[39]. Advanced glycation end-products, which are ca-
pable of generating ROS, have also been found in
NFT [40,41] and NP [42]. Protein carbonyls, indica-
tors of protein oxidation, and peroxynitrate, a reac-
tion product of nitric oxide and the superoxide
radical, have been documented in NFT by immuno-
histochemical techniques [43,44]. In addition, the ac-
tivities of key antioxidant enzymes, particularly cat-
alase, was reduced, suggesting that AD brain may be
vulnerable to increased ROS production [45]. In re-
lated reports, it has been shown that L-amyloid may
generate free radicals in aqueous solution [46] and
produce oxidative damage in hippocampal neurons
[47].
There is also evidence that L-amyloid impairs the
activity of the mitochondrial respiratory chain. This
is best illustrated by inclusion body myositis (IBM),
a common myopathy developing in patients over the
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age of 50 years. Morphologically, IBM is character-
ized by the presence of vacuolated muscle ¢bers
showing accumulations of L-APP and 15- to 21-nm
paired helical ¢laments containing hyperphosphory-
lated tau [48]. The transfer of a cDNA encoding
APP751 into human myoblasts produced abnormal-
ities of mitochondrial structure and function [49].
Decrease in the histochemical staining for cyto-
chrome c oxidase (COX) was observed after 24 h,
becoming virtually complete in 80% of ¢bers at
2 weeks. Electron microscopy at 3^4 weeks
showed abnormal mitochondria structure, including
the presence of intramitochondrial paracrystalline in-
clusions.
There is also evidence of oxidative damage to both
mtDNA and nDNA, documented by measuring the
oxidized radical adduct 8-hydroxy-2P-deoxyguano-
sine (8OHdG). The mtDNA appears to be more sus-
ceptible to accumulating oxidative damage than is
nDNA. 8OHdG levels were higher in human brain
mtDNA than in nDNA, and increased with age in
human muscle and brain [50]. Studies in AD brains
have shown preferential accumulation of 8OHdG in
the mtDNA over the nuclear DNA, and signi¢cantly
higher levels of 8OHdG in AD than in control brains
[51]. In one study, the enhanced oxidative damage
was associated with increased levels of the ‘common
deletion’ in cortical regions of AD patients who died
after age 75 years [52], although we were not able to
con¢rm these ¢ndings (unpublished data).
5. Mitochondrial dysfunction in AD
Altered brain energy metabolism is an early and
prominent feature of AD [53]. As the disease pro-
gresses, signi¢cant decreases in oxygen and glucose
utilization have been shown by positron emission
tomography (PET) [54]. These ¢ndings are consistent
with the notion that the reduction in glucose metab-
olism in vivo re£ects reduced neuronal oxidative ac-
tivity. PET has documented visually the evolution of
the metabolic alterations in the AD neocortex. An
early de¢cit in glucose metabolism is seen in the pa-
rietal and temporal regions, areas with particularly
high density of NP [55]. In longitudinal studies, it has
been documented that metabolic reductions in the
parietal association cortex precede the impairment
of such neocortical-mediated functions as language
and visuospatial recognition [56].
More direct evidence for a defect of energy metab-
olism in AD comes from several reports of COX
de¢ciency in AD brain. Mitochondria freshly pre-
pared from nine entire AD hemi-brains showed a
40% decrease in complex I and a 53% reduction in
COX activity [57,58]. When COX activity was meas-
ured in homogenates from AD brain, less severe, but
statistically signi¢cant, decreases were found in fron-
tal and temporal cortices [59]. In a study using both
homogenates and mitochondrial preparations from
19 AD patients, COX activity (corrected for citrate
synthase activity) was decreased by 27% in temporal
cortex extracts and by 25^30% in mitochondrial frac-
tions from various cortical areas [60]. Another study
using tissue homogenates of frontal and parietal cor-
tex found 34 and 38% reduction in COX activity,
respectively [61].
In agreement with these biochemical observations,
histochemical data by Simonian et al. [62] showed
signi¢cant reduction of COX activity in the molecu-
lar layer of the dentate gyrus and in other sub¢elds
of the hippocampal formation of AD patients. Fi-
nally, in situ hybridization studies showed decreased
mRNA levels of the mtDNA-encoded subunit II, but
not the nDNA-encoded subunit IV, of COX [63].
Based on these observations, and to gain further
insight into the pathogenesis of mitochondrial dys-
function in AD, we have initiated a study of the
expression of subunits of the respiratory chain in
the hippocampal formation from patients with AD
and from normal controls. We studied the expression
of two subunits of COX (mtDNA-encoded COX I
and COX II) and of one subunit of Complex III
(nDNA-encoded FeS subunit) by immunohistochem-
istry, using the immunoperoxidase method [64].
In normal controls, we observed immunoreaction
with all antibodies in the molecular layer of the den-
tate gyrus (Fig. 1a,b). The cell bodies of the granule
cells showed a ¢nely punctate pattern of immuno-
reactivity. In the hilus, CA3, CA2, CA1, and in the
subiculum (Fig. 2a,b), the immunoreaction was seen
throughout the neuropil and in the perikaryon and
dendrites of neurons. In the hippocampal formation
of the AD patients, on the other hand, immunoreac-
tion with all antibodies was reduced in the molecular
layer of the dentate gyrus, in the cell bodies of gran-
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Fig. 1. Immunostaining of sections of the dentate gyrus from a normal individual (a,b) and an AD patient (c,d) for the localization
of the mtDNA-encoded COX II subunit of Complex IV (a,c) and the nDNA-encoded FeS subunit of Complex III (b,d). The patient
with Alzheimer’s disease shows a marked decrease of immunostain for COX II and for FeS in granule cells (arrow) and in the molec-
ular layer (ML) of the dentate gyrus.
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ule cells (Fig. 1c,d) and in all hippocampal sub¢elds,
including neurons with and without NFT formation
(Fig. 2c,d).
While our results con¢rmed the original observa-
tions of Simonian and co-workers [62,63] that there
is COX de¢ciency in AD hippocampus, it is note-
worthy that we found a reduction not only of
mtDNA-encoded COX I and COX II subunits, but
Fig. 2. Immunostaining of sections of the CA1 region of the hippocampal formation from a normal control (a,b) and from the same
AD patient shown in Fig. 1 (c,d) for the localization of the mtDNA-encoded COX II subunit of Complex IV (a) and the nDNA-en-
coded FeS subunit of Complex III (b). Note the decreased immunostain for both COX II and FeS in the AD patient; this decrease
appears to occur in the vast majority of neurons, whether they contain NFT (arrows) or not.
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also of the nDNA-encoded FeS subunit of Complex
III. The anatomic distribution of the reduced immu-
noreactivity for subunits of the respiratory chain was
similar to the distribution observed by Simonian
et al. for the reduction in COX II mRNA levels
[63].
We note that both mtDNA-encoded and nDNA-
encoded subunits of the respiratory chain appear to
be highly sensitive to alterations in neuronal func-
tion. For instance, following monocular deprivation
in monkeys, Hevner and Wong-Riley found de-
creased mRNA levels of both the mtDNA-encoded
COX I and the nDNA-encoded COX IV subunits in
speci¢c layers of the lateral geniculate nuclei [65].
These observations suggest that alterations in COX
activity as a result of dea¡erentation may be con-
trolled primarily by nuclear factors regulating the
expression of the respiratory chain [66]. Although
our results must also represent secondary changes
due to dea¡erentation of hippocampal sub¢elds,
they provide further evidence for mitochondrial dys-
function in AD.
Nor is evidence for mitochondrial dysfunction in
AD con¢ned to alterations in COX or to mitochon-
dria of the hippocampal formation. For example,
cortical tissue from AD brain shows decreased activ-
ity of ATP-synthase [67], pyruvate dehydrogenase
[68], and K-ketoglutarate dehydrogenase [69], impor-
tant enzymes in energy metabolism that are mito-
chondrial, but are not part of the respiratory chain.
In addition, there is evidence of reduced mRNA lev-
els of both mitochondrial and nuclear genes in the
temporal cortex, but not in the primary motor cortex
of AD brain. Messenger RNAs for two subunits of
Complex I (ND1 and ND4), and for COX I, COX II
and COX III, all of which are mtDNA-encoded
genes, are also reduced in AD temporal cortex [70],
but so are the mRNAs for the L-subunit of ATP
synthase and for COX IV, which are nuclear genes.
In contrast, mRNA for proteins that are not compo-
nents of the respiratory chain, such as lactate dehy-
drogenase, L-actin, and mtDNA-encoded 12S rRNA,
are not reduced. These observations have led to the
proposal that in AD there is a global down-regula-
tion of the expression of all subunits of the respi-
ratory chain, but the precise mechanisms under-
lying this down-regulation remain to be elucidated
[70^73].
6. Mitochondrial DNA mutations in AD
While there is increasing evidence that mitochon-
drial functions may be impaired in AD, the patho-
genic role of mtDNA mutations is controversial at
best. To understand the underlying issues in this con-
troversy, it is important to distinguish somatic cell
mutations from maternally inherited mtDNA muta-
tions. An example of somatic cell mtDNA mutations
is the putative increased levels of the ‘common dele-
tion’ in cerebral cortex of AD patients [52], which
has not been corroborated [70,74,75] and, in fact,
was not con¢rmed by us (unpublished data). By con-
trast, several reports have suggested that maternally
inherited point mutations of mtDNA might play a
pathogenic role in AD.
The concept that maternally inherited mtDNA
mutations can contribute to AD is appealing for at
least three reasons. First, over 50 mtDNA point mu-
tations have been identi¢ed, many in patients with
neurodegenerative conditions [19,20], leading some
investigators to hypothesize that the mitochondrial
encephalomyopathies might be a ‘paradigm for de-
generative diseases’ such as AD [6]. Second, there are
at least two epidemiological reports suggesting that
there may be a higher incidence of AD in mothers
compared to fathers of AD probands, implying pos-
sible maternal inheritance [53,76]. Third, and perhaps
most importantly, the hypothesis is testable.
The ¢rst such candidate mutation was reported in
1992 [77]. It was a GCA transition at position 5460
in ND3 gene; it was found in 10 of 19 AD brains,
but was absent in all 11 controls studied. These re-
sults, however, could not be con¢rmed [78^81], and it
appears that the G5460A mutation is almost cer-
tainly a neutral polymorphism.
The etiology ascribed to a second point mutation ^
an ACG transition at position 4336 in tRNAGln ^ is
less clear. Using restriction endonuclease analyses,
Sho¡ner et al. [82] attempted to identify di¡erences
in mtDNA from 173 late-onset Caucasian patients
with AD, Parkinson’s disease (PD), or both. Only
the A4336G polymorphism showed a modestly in-
creased frequency in the patients (9/173, or 5.2%)
compared to controls (12/1691, or 0.7%). A second
group reported similar results, with a slightly higher
incidence of this polymorphism in patients with AD
(1/28, or 3.6%) and PD (2/23, or 8.7%) as compared
BBABIO 44702 29-1-99 Cyaan Magenta Geel Zwart
E. Bonilla et al. / Biochimica et Biophysica Acta 1410 (1999) 171^182 177
to controls (0/100) [83]. A third group also found an
elevated frequency of the A4336G mutation in AD
patients [84], but cladistic analysis of the mtDNA
haplotypes indicated that there was a potential
‘founder e¡ect’ for this mutation, implying that it
is not the mutation per se that is etiologic, but rather
that AD patients may harbor a mitochondrial geno-
type that predisposes to the disease. By contrast, a
fourth study found a lower rate of this polymorphism
in AD patients (1/155, or 0.6%) than in age-matched
controls (4/105, or 4%) [85]. A ¢fth group found no
segregation of the mutation in 100 PD patients [86].
To explore the issue of mtDNA mutations in AD
in greater depth, the mitochondrial genome was se-
quenced in three patients with AD plus PD, and in
one patient with PD alone [87]. Several mtDNA
polymorphisms were identi¢ed in this group of pa-
tients, including A4336G; however, none of the poly-
morphisms was common to all of the patients and all
could have been due to the normal variation in hu-
man mtDNA. Thus, the pathogenic role of those
polymorphisms could not be established. In sum,
while these results are intriguing, the A4336G poly-
morphism might be a marker for mtDNA involve-
ment in some cases of AD, but it is unlikely to play a
signi¢cant role in the vast majority of patients.
In a study published last year, Davis and col-
leagues described the identi¢cation of six novel
mtDNA point mutations in both AD patients and
in control individuals, and furthermore, they re-
ported that the proportion of these polymorphisms
was signi¢cantly higher in platelet-enriched DNA
from the AD patients [88]. Three of the putative
mutations were in the subunit I gene of COX
(G6366A, C6483T, and A7146G) while the other
three were in the subunit II gene of COX (C7650T,
C7868T, and A8021G). However, in subsequent
studies, these purported mtDNA mutations were
identi¢ed as artifacts derived from PCR ampli¢ca-
tion of nuclear DNA, speci¢cally, from nucleus-em-
bedded mtDNA pseudogenes [89,90].
In addition to direct sequencing of mtDNA, the
cybrid tissue culture system has also been utilized to
identify possible mtDNA alterations in AD patients.
This in vitro system uses cells devoid of mtDNA,
called b‡ cells [91]. These cells can be fused with
cytoplasts derived from cells harboring known or
potentially pathogenic mtDNA mutations, thereby
creating ‘cytoplasmic hybrids’ or ‘cybrids.’ They
have been successfully used to investigate the patho-
genic e¡ects of candidate mtDNA mutations in a
uniform nuclear background [92]. In one study uti-
lizing the cybrid technology, a teratocarcinoma cell
line (NT2) reported to be depleted of mtDNA [93]
was fused with platelets from ¢ve AD patients and
from four control individuals [94]. The cybrids de-
rived from the AD patient platelets were found to
have evidence of increased reactive oxygen species
and free radical scavenging enzyme activities, with
a biochemical defect in COX activity [94] and in
calcium homeostasis [95] when compared to cybrids
from control platelets. Unfortunately, several meth-
odological issues have been raised regarding the ap-
propriateness of these lines in ascribing the cause for
the observed defects to authentic mtDNA mutations
[96]. Thus, the interpretation of the data is unclear at
present.
In short, while oxidative phosphorylation may be
compromised in AD, there are no convincing data to
implicate either sporadically derived mtDNA dele-
tions or maternally inherited mtDNA point muta-
tions in the majority of AD patients.
7. Concluding remarks
The causes of most neurodegenerative diseases, in-
cluding sporadic AD, remain enigmatic. There is,
however, increasing evidence implicating mitochon-
drial dysfunction resulting from dea¡erentiation of
disconnected neural circuits in the pathogenesis of
energy de¢cit in AD. The patterns of reduced expres-
sion of both mtDNA and nDNA-encoded genes are
consistent with a physiological down-regulation of
the mitochondrial respiratory chain in response to
reduced neuronal activity. On the other hand, the
roles of somatic cell or maternally inherited mtDNA
mutations in the pathogenesis of mitochondrial dys-
function in AD are still controversial. It is particu-
larly interesting that the increase in oxidative damage
in mtDNA is associated with increased levels of the
‘common deletion’ in cortical regions of AD patients.
These observations suggest that AD patients may
have elevated oxidative damage, which may increase
the somatic mtDNA mutation rate. It is important,
however, to emphasize that this observation has not
BBABIO 44702 29-1-99 Cyaan Magenta Geel Zwart
E. Bonilla et al. / Biochimica et Biophysica Acta 1410 (1999) 171^182178
been corroborated by other investigators, and that
no direct cause-and-e¡ect relationship has yet been
established between oxidative damage to mtDNA
and mtDNA mutations in AD or in aging. More
work on this area is required before this hypothesis
can be considered fully substantiated.
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